Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1096/18 (Dry powder composition for inhalation / SIMA PATENT) 05-03-2021
Facebook X Linkedin Email

T 1096/18 (Dry powder composition for inhalation / SIMA PATENT) 05-03-2021

European Case Law Identifier
ECLI:EP:BA:2021:T109618.20210305
Date of decision
05 March 2021
Case number
T 1096/18
Petition for review of
-
Application number
10778746.7
IPC class
A61K31/137
A61K9/00
A61K31/58
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 378.04 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

THE PHARMACEUTICAL COMPOSITION IN DRY POWDER FORM FOR INHALATION

Applicant name
Sima Patent ve Lisanslama Hizmetleri Ltd.Sti.
Opponent name
Wuesthoff & Wuesthoff Patentanwälte PartG mbB
Board
3.3.01
Headnote
-
Relevant legal provisions
European Patent Convention 056 (2007)
Keywords

Inventive step - all requests (no)

Inventive step - obvious combination of known features

Catchword
-
Cited decisions
-
Citing decisions
-

I. European patent No. 2 490 681 ("the patent") is based on European patent application No. 10778746.7. The patent was granted with eight claims.

Claim 1 reads as follows:

"1. A pharmaceutical composition containing a combination comprised of a corticosteroid and a beta2-agonist characterized in that

• the components of said combination are in the dry powder form,

• the average particle size of the active agents is less than 20 µm,

• two active agents contained in said pharmaceutical composition are together with lactose as carrier and they are stored in a peelable, aluminium blister strip, wherein the cavity volume of the blister is in the range of 22 to 23 mm3 and each blister cavity is filled up to 70-100 % of said volume,

• said pharmaceutical composition is suitable to be administered to a patient by a device suitable for dry powder."

II. Opposition proceedings were based on the grounds for opposition under Article 100(a) EPC for lack of novelty and lack of inventive step and under Article 100(b) and (c) EPC.

III. The documents filed during the opposition proceedings included:

D7: WO 2006/066908 A1

D12: EP 0 743 912 B1

D13: Technical report dated 25 August 2017 entitled "Effect of filled volume in blister cavity on delivered drug dose" (six pages in total)

IV. The opposition division's decision to revoke the patent was based on a main request and thirty-eight auxiliary requests. The main request was the patent as granted. The sets of claims of auxiliary requests 1 to 38 were all filed on 25 August 2017.

In the decision under appeal, the opposition division concluded inter alia that the subject-matter of claim 1 of the main request was obvious in view of document D7 taken in combination with document D12. The same held true for claim 1 of each of the auxiliary requests. The opposition division also decided to admit document D13 into the proceedings.

V. The patent proprietor ("appellant") lodged an appeal against the opposition division's decision.

VI. In the statement setting out the grounds of appeal, the appellant requested that the decision under appeal be set aside and, as its main request, that the patent be maintained as granted, i.e. that the opposition be rejected. As an auxiliary measure, the appellant requested that the patent be maintained in amended form on the basis of one of the sets of claims of auxiliary requests 2 to 38 considered in the impugned decision.

Claim 1 according to auxiliary requests 2 and 3 is identical to claim 1 of the main request (see point I. above).

Claim 1 of auxiliary request 4 differs from claim 1 of the main request in that the peelable, aluminium blister strip is further specified as "comprising a base sheet and a lid sheet, the base sheet comprising blister cavities and the lid sheet being peelable from the base sheet" (i.e. feature (i)).

Claim 1 of auxiliary request 5 differs from claim 1 of the main request in that the following passage was added at the beginning of the claim:

"A peelable, aluminium blister strip and" (i.e. feature (ii)).

Claim 1 of auxiliary request 6 differs from claim 1 of the main request in that the following passage was added at the end of the claim:

"• the weight ratio of a corticosteroid or a pharmaceutically acceptable salt thereof to a beta2-agonist or a pharmaceutically acceptable salt thereof is in the range of 1:1 to 100:1, preferably 1:1 to 60:1" (i.e. feature (iii)).

Claim 1 according to auxiliary requests 7 to 9 is identical to claim 1 of auxiliary requests 4 to 6, respectively.

Claim 1 of auxiliary request 10 includes, in combination, the amendments made to claim 1 of auxiliary requests 4 and 5, respectively, i.e. features (i) and (ii).

Claim 1 of auxiliary request 11 includes, in combination, the amendments made to claim 1 of auxiliary requests 4 and 6, respectively, i.e. features (i) and (iii).

Claim 1 of auxiliary request 12 includes, in combination, the amendments made to claim 1 of auxiliary requests 4, 5 and 6, respectively, i.e. features (i), (ii) and (iii).

Claim 1 according to auxiliary requests 13 to 24 is identical to claim 1 according to the main request and auxiliary requests 2 to 12, respectively, with the exception that lactose is specified as "being present in the range of 0-50 mg in the dry powder".

Claim 1 of auxiliary request 25 differs from claim 1 of auxiliary request 13 in that each blister cavity is filled up to 90-100% of the cavity volume of the blister.

Claim 1 of auxiliary requests 26 to 37 is identical to claim 1 according to the main request and auxiliary requests 2 to 12, respectively, with the exception that lactose is specified as "being present in an amount of up to 50 mg in the dry powder".

Claim 1 of auxiliary request 38 differs from claim 1 of auxiliary request 26 in that each blister cavity is filled up to 90-100% of the cavity volume of the blister.

VII. In its reply to the statement setting out the grounds of appeal, the opponent ("respondent") requested inter alia that the appeal be dismissed.

VIII. In the course of the appeal proceedings, the board issued a communication pursuant to Article 15(1) RPBA 2020 dated 26 February 2020 ("communication of 26 February 2020") setting out its preliminary opinion on relevant issues.

IX. The parties were summoned to oral proceedings in view of their requests to that effect. On 16 February 2021, the format of the oral proceedings was changed to a videoconference and a date was fixed for submitting any comments or objections in relation to holding the oral proceedings by videoconference. No comments or objections were received by the fixed date.

X. In a letter dated 1 March 2021, the appellant informed the board that it would not be attending the oral proceedings.

XI. Oral proceedings were held by videoconference on 5 March 2021 in the presence of the respondent only.

XII. At the end of the oral proceedings, the chairman announced the board's decision.

XIII. The appellant's case relevant for the present decision may be summarised as follows:

Main request - inventive step

The subject-matter of claim 1 of the main request differed from the closest prior art, document D7, on account of the claimed storage means, the claimed average particle size of the active agents and the selection of lactose as the carrier. On the basis of the experimental data provided in document D13, the objective technical problem to be solved by the claimed invention was that of providing a blister strip that comprised a combination of a corticosteroid and a beta2-agonist with an improved mean delivered dose and greater delivered-dose uniformity. Contrary to the opposition division's view, the skilled person would not have combined document D12 with the closest prior art to solve the stated technical problem. Hence, the solution proposed in claim 1 was inventive.

The same conclusions applied if the objective technical problem were to be considered that of providing an alternative dry-powder composition.

Auxiliary requests 2 to 38 - inventive step

The subject-matter of each of these requests was inventive for the same reasons as the main request.

XIV. The respondent's case relevant for the present decision may be summarised as follows:

All requests - inventive step

The closest prior art, document D7, disclosed (page 15, lines 19 to 21) a blister pocket having a volume of 21 mm3**()and a filling percentage of 81%. Claim 1 differed from this disclosure in that the claimed blister cavities had higher volumes of 22 to 23 mm**(3). Since the results of document D13 relied on by the appellant to corroborate the alleged improved mean delivered dose and greater delivered-dose uniformity were not meaningful, the objective technical problem was to be worded as providing an alternative dry-powder composition. Contrary to the appellant's opinion, the skilled person faced with this problem would have combined document D7 with document D12, paragraph [0021] of which disclosed cavity volumes of up to 25 mm**(3). In the light of this teaching, it would have been obvious for the skilled person looking for an alternative dry-powder composition to select the claimed cavity volume of 22 to 23 mm**(3).

XV. The parties' final requests, in so far as relevant to the present decision, were as follows:

The appellant's final requests were identical to those set out in point VI. above.

The respondent requested that the appeal be dismissed.

1. The appeal complies with Articles 106 to 108 EPC and Rule 99 EPC and is admissible.

2. Absence of the appellant from the oral proceedings

2.1 The appellant had been duly summoned but chose not to attend the oral proceedings, as announced in its letter of 1 March 2021.

2.2 In accordance with Rule 115(2) EPC and Article 15(3) RPBA 2020, the board decided to continue the proceedings in the appellant's absence and to treat the appellant as relying on its written case. By absenting itself from the oral proceedings the appellant waived the opportunity to make any further submissions on the relevant issues of the case.

Hence, the board was in a position to announce a decision at the conclusion of the oral proceedings, as provided for in Article 15(6) RPBA 2020.

Main request (patent as granted)

3. The subject-matter of claim 1

Claim 1 is directed to a pharmaceutical composition containing

(a) a combination comprised of a corticosteroid and a beta2-agonist ("feature (a)") characterised in that

(b) the components of said combination are in the dry powder form ("feature (b)"),

(c) the average particle size of the active agents is less than 20 µm ("feature (c)"),

(d) the two active agents contained in said pharmaceutical composition are together with lactose as carrier ("feature (d)") and

(e) they are stored in a peelable, aluminium blister strip ("feature (e.1)"), wherein:

(i) the cavity volume of the blister is in the range of 22 to 23 mm**(3) ("feature (e.2)") and

(ii) each blister cavity is filled up to 70-100% of said volume ("feature (e.3)"),

(f) said pharmaceutical composition is suitable to be administered to a patient by a device suitable for dry powder.

4. Article 100(a) EPC in conjunction with Article 56 EPC

Closest prior art

4.1 As held by the opposition division and in agreement with the parties, the board considers document D7 to be the closest prior art.

4.2 This document describes a manifold for use in a medication dispenser device for delivering a medication powder from an open blister pocket of a blister pack (see page 2, lines 22 to 24). As submitted by the appellant, the focus of document D7 is on the manifold as such. However, this disclosure also provides detailed information on the medication powder and the blister pack containing it. For instance, it is stated on page 49, second paragraph that appropriate medications include combinations of a corticosteroid and a beta2-adrenoreceptor agonist (i.e. feature (a) of claim 1). Details on the blister pack may be found on page 15, lines 19 to 21, which describes an example blister pocket that is spherical with a radius of 1.7 mm and a cross-sectional area of 8.0 mm**(2). The blister pocket contains 17 myl of a medication powder.

4.3 In the light of the above considerations, the board does not accept the appellant's statement that "D7 remains a fundamentally non-obvious starting point" (see page 7, penultimate paragraph of the statement setting out the grounds of appeal).

Distinguishing features vis-à-vis document D7

4.4 The board agrees with the appellant that the subject-matter of claim 1 differs from document D7 on account of features (c), (d), (e.1), (e.2) and (e.3) (see point 3. above).

Objective technical problem and solution

4.5 The objective technical problem is to be specified on the basis of the technical effects that the distinguishing features provide over the closest prior art.

4.6 On the basis of the comparative experiments disclosed in document D13, in its statement setting out the grounds of appeal the appellant submitted that features (e.2) and (e.3) each provided a superior mean delivered dose and superior delivered-dose uniformity compared with the blister packs disclosed in document D7, and formulated the objective technical problem accordingly (see point XIII. above).

4.7 In response to the statement setting out the grounds of appeal, the respondent questioned the meaningfulness of the experimental results in document D13, arguing that the comparative experiments lacked detail (see pages 12 and 13 of the reply to the statement setting out the grounds of appeal).

4.8 This issue was subsequently addressed in the board's communication of 26 February 2020. In point 2.9 of this communication, the board stated that it was minded to agree with the respondent that the experimental data in document D13 could not form a proper basis for specifying the objective technical problem addressed by the claimed invention.

4.9 The appellant did not submit any facts or substantive arguments in response to the board's communication of 26 February 2020, instead merely confirming its requests and announcing that it would not be attending the oral proceedings (see point X. above).

4.10 Under these circumstances, the board sees no reason to change its preliminary opinion. Accordingly, in the absence of reliable comparative data, the alleged improvements brought about by features (e.2) and (e.3) cannot be taken into consideration when formulating the objective technical problem.

4.11 The board further notes that the appellant has not invoked any particular technical effect in connection with any of the distinguishing features (c), (d) and (e.1), either individually or in combination with any other feature of claim 1. The board is likewise unable to identify any such effect and therefore agrees with the opposition division's formulation of the objective technical problem as that of providing an alternative dry-powder composition.

4.12 As a solution to this problem, the claimed invention proposes the pharmaceutical composition recited in claim 1.

Assessment of obviousness

4.13 In the decision under appeal, the opposition division concluded that distinguishing features (c) and (d) did not contribute to inventive step having regard to the teachings on page 49, last paragraph and page 50, first paragraph of document D7 (see point 17.5.1 of the decision). In the absence of any arguments to the contrary on the appellant's part, the board sees no reason to deviate from the opposition division's finding.

4.14 Distinguishing features (e.1), (e.2) and (e.3) cannot contribute to an inventive step either, for the following reasons.

Feature (e.1), i.e. a peelable, aluminium blister strip

4.14.1 The appellant has not based any argument in support of an inventive step on this feature. Hence, the board can only conclude that feature (e.1) is not suitable for establishing an inventive step.

Feature (e.2), i.e. a blister cavity volume of 22 to 23 mm**(3)

4.14.2 This feature is obvious from paragraph [0021] of document D12, which indicates that the cavities of the elongate carrier preferably have a volume of between 0.5 and 25 mm3.

Feature (e.3) specifying the filling percentage of each blister cavity to be 70-100% of the blister cavity volume

4.14.3 On page 15, lines 19 to 21, document D7 discloses an example blister pocket (see point 4.2 above). In the oral proceedings the respondent submitted that this blister pocket had a volume of 21 mm**(3)and a filling percentage falling within the claimed range (i.e. 81%), as evidenced by its calculations presented in writing before the opposition division.

4.14.4 These calculations are analysed in more detail in point 15 of the impugned decision (see fourth paragraph; the reference in this section to "page 8, [0001] to [0003] of O1 letter dated 04-08-2017" appears to be an error, the correct reference being "page 8, paragraphs 1 to 3 of the notice of opposition"). The opposition division did not express any doubts concerning the correctness of the respondent's calculations. It concluded that the example blister pocket in document D7 differed from the blister cavity recited in claim 1 on account of features (e.1) and (e.2) only.

4.14.5 In the absence of any arguments to the contrary on the appellant's part, the board does not see any reason to depart from the opposition division's finding. It follows that feature (e.3) is already disclosed in document D7 and therefore cannot contribute to the presence of an inventive step either.

Conclusion on obviousness

4.15 In sum, the board finds that in the absence of a particular technical effect attributable to the combination of any of the distinguishing features (c), (d), (e.1) and (e.2) with any other feature of claim 1 (see point 4.11 above), the claimed invention amounts to a mere aggregation of obvious features which is devoid of any inventive merit.

Appellant's arguments

4.16 The appellant argued that the skilled person would not have combined document D7 with document D12 because D12:

(a) was concerned with a different technology from document D7 ("argument (a)")

(b) did not actually disclose a blister having a cavity volume of 22 to 23 mm**(3) ("argument (b)")

(c) did not prompt the skilled person to change the cavity volume of document D7 in view of the constraints that the inhaler device disclosed on page 16, fourth paragraph of D7 imposed on the pharmaceutical composition and the blister pack comprising it ("argument (c)")

4.17 These arguments are not convincing.

Argument (a)

4.17.1 As set out in point 4.2 above, document D7 is not only concerned with manifolds per se but also goes into detail on dry-powder medications and blister packs containing them. Document D12, in turn, generally relates to devices for filling these dry-powder medications into cavities of an elongate carrier with a high degree of accuracy (see paragraph [0013]). As submitted by the respondent at the oral proceedings, this kind of filling is a routine consideration when trying to formulate a composition in accordance with document D7. Hence, the skilled person searching for a solution to the objective technical problem of providing an alternative dry-powder composition would have consulted document D12 and taken its content into consideration. Accordingly, argument (a) cannot succeed.

Argument (b)

4.17.2 It is undisputed that D12 does not specify the claimed cavity volume of 22 to 23 mm**(3). However, from paragraph [0021] of this document the skilled person learns that, in preferred embodiments, the cavities of the elongate carrier could have a volume of between 0.5 and 25 mm3. Hence, the claimed cavity volume range constitutes a sub-range of the broader range disclosed in document D12. For the reasons indicated in points 4.6 to 4.10 above, the board cannot acknowledge any particular effect or advantage arising from the values in this sub-range. Accordingly, the selection of the claimed sub-range amounts to an arbitrary choice of values from among the broader range of 0.5 to 25 mm**(3) disclosed in document D12. As argued by the respondent at the oral proceedings, this kind of mere arbitrary choice is within the capabilities of the skilled person seeking an alternative dry-powder composition.

Argument (c)

4.17.3 Contrary to the appellant's view, the choice of the claimed cavity volume range is not governed by any constraints imposed by the inhaler device disclosed on page 16, fourth paragraph of document D7. As convincingly argued by the respondent at the oral proceedings, blister packs containing dry-powder compositions and inhaler devices are two separate, distinct entities. Accordingly, to solve the objective technical problem of providing an alternative dry-powder composition, the composition need not be stored in a blister pack that is specifically adapted to the inhaler device disclosed on page 16, fourth paragraph of document D7.

Overall conclusion on inventive step of the main request

4.18 In the light of the above considerations, the board does not see any reason to deviate from the opposition division's conclusion that the subject-matter of claim 1 lacks inventive step. It follows that the ground for opposition under Article 100(a) EPC in conjunction with Article 56 EPC prejudices the maintenance of the patent as granted.

Auxiliary requests 2 to 38

5. In the statement setting out the grounds of appeal, the appellant submitted that the subject-matter of each of auxiliary requests 2 to 38 was inventive for the same reasons as the main request. No further arguments were presented in relation to these requests.

6. Under these circumstances, the board can only conclude that claim 1 of each of auxiliary requests 2 to 38 does not overcome the objection of lack of inventive step for the same reasons as claim 1 of the main request.

Overall conclusion

7. Since none of the claim requests is allowable, the appeal is to be dismissed.

Order

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility